Market Research Industry Reports

TESARO Inc (TSRO) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

TESARO Inc (TESARO) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates and discovery of new candidates. It develops products using different approaches, comprising small molecules and immuno-oncology antibodies. The companys product portfolio includes ZEJULA (niraparib), to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and VARUBI (rolapitant) for the prevention of chemotherapy induced nausea and vomiting (CINV). TESARO sells its products directly to hospitals and clinics, and to a limited number of specialty distributors and pharmacy providers in the US and to certain wholesale distributors in Europe. TESARO is headquartered in Waltham, Massachusetts, the US.

TESARO Inc (TSRO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TESARO Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10
TESARO Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
TESARO Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Tesaro Enters into Collaboration Agreement with Genentech 13
Tesaro and Medison Pharma Enter into Distribution Agreement 14
Tesaro Enters into Partnership with Genentech 15
Evotec and Tesaro Enter into Agreement 16
OncoQuest Enters into Agreement with Tesaro 17
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 18
Licensing Agreements 19
TESARO Enters into Research and Licensing Agreement with TeneoBio 19
Millennium Pharma Enters into Licensing Agreement with Tesaro 20
Zai Lab Enters into Licensing Agreement with Tesaro 21
Janssen Biotech Enters into Licensing agreement with Tesaro 22
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 23
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 24
Tesaro Amends Licensing Agreement With AnaptysBio 25
Tesaro Enters into Licensing Agreement with AstraZeneca 26
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 27
Equity Offering 28
Tesaro Raises USD236.3 Million in Public Offering of Shares 28
Tesaro Raises USD433.2 Million in Public Offering of Shares 30
Tesaro Raises USD50 Million in Private Placement of Shares 32
Tesaro Raises up to USD155 Million in Private Placement of Shares 33
Tesaro Raises USD191.5 Million in Public Offering of Shares 35
Tesaro Completes Public Offering Of Shares For US$100.8 Million 37
Tesaro Completes Public Offering Of Common Stock For US$98 Million 38
Tesaro Announces Partial Exercise Of Underwriters Option For IPO For US$87 Million 39
Debt Offering 41
Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 41
Acquisition 43
Tesaro May Sell Itself 43
TESARO Inc - Key Competitors 44
TESARO Inc - Key Employees 45
TESARO Inc - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Financial Announcements 47
May 03, 2018: TESARO Announces First-Quarter 2018 Operating Results 47
Feb 27, 2018: TESARO Announces Fourth-Quarter and Full-Year 2017Operating Results 49
Nov 07, 2017: TESARO Announces Third-Quarter 2017 Operating Results 53
Aug 08, 2017: TESARO Announces Second-Quarter 2017 Operating Results 55
May 09, 2017: TESARO Announces First-Quarter 2017 Operating Results 57
Feb 28, 2017: TESARO Announces Fourth-Quarter 2016 Operating Results 59
Government and Public Interest 61
May 08, 2018: Psychological Effects of Ovarian Cancer Often Overlooked But Can Have a Significant Impact on Patients 61
Product News 63
10/25/2017: TESARO Announces U.S. FDA Approval of VARUBI IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy 63
02/27/2017: TESARO Receives Positive CHMP Opinion for VARUBY 65
02/23/2017: Tesaro Receives CHMP Positive Opinion for Varuby (rolapitant) 66
01/12/2018: TESARO Announces Updates to the U.S. Prescribing Information for VARUBI (rolapitant) Injectable Emulsion 67
Product Approvals 68
Sep 11, 2017: NHS Scotland Recommends Tesaros Varuby (Rolapitant) For Delayed Nausea And Vomiting In Adults Undergoing Highly Emetogenic Chemotherapy 68
Apr 26, 2017: TESARO Announces Approval of VARUBY (Oral Rolapitant Tablets) by European Commission 69
Jan 11, 2017: TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA 71
Clinical Trials 72
Nov 28, 2017: TESARO Announces Availability of VARUBI (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States 72
Sep 11, 2017: TESARO Summarizes TSR-042 Data Presented at 2017 ESMO Annual Meeting 74
Aug 25, 2017: TESARO Presents Poster on TSR-042 at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting 75
Apr 27, 2017: TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042 76
Other Significant Developments 77
Jun 03, 2017: TESARO Provides Business and Pipeline Update at ASCO Investor Briefing 77
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80

List Of Tables

List of Tables
TESARO Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TESARO Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TESARO Inc, Deals By Therapy Area, 2012 to YTD 2018 9
TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10
TESARO Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Tesaro Enters into Collaboration Agreement with Genentech 13
Tesaro and Medison Pharma Enter into Distribution Agreement 14
Tesaro Enters into Partnership with Genentech 15
Evotec and Tesaro Enter into Agreement 16
OncoQuest Enters into Agreement with Tesaro 17
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 18
TESARO Enters into Research and Licensing Agreement with TeneoBio 19
Millennium Pharma Enters into Licensing Agreement with Tesaro 20
Zai Lab Enters into Licensing Agreement with Tesaro 21
Janssen Biotech Enters into Licensing agreement with Tesaro 22
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 23
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 24
Tesaro Amends Licensing Agreement With AnaptysBio 25
Tesaro Enters into Licensing Agreement with AstraZeneca 26
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 27
Tesaro Raises USD236.3 Million in Public Offering of Shares 28
Tesaro Raises USD433.2 Million in Public Offering of Shares 30
Tesaro Raises USD50 Million in Private Placement of Shares 32
Tesaro Raises up to USD155 Million in Private Placement of Shares 33
Tesaro Raises USD191.5 Million in Public Offering of Shares 35
Tesaro Completes Public Offering Of Shares For US$100.8 Million 37
Tesaro Completes Public Offering Of Common Stock For US$98 Million 38
Tesaro Announces Partial Exercise Of Underwriters Option For IPO For US$87 Million 39
Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 41
Tesaro May Sell Itself 43
TESARO Inc, Key Competitors 44
TESARO Inc, Key Employees 45
TESARO Inc, Subsidiaries 46

List Of Figures

List of Figures
TESARO Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TESARO Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10

TESARO Inc (TSRO) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

TESARO Inc (TESARO) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates and discovery of new candidates. It develops products using different approaches, comprising small molecules

USD 250View Report

TESARO Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

TESARO Inc Company Profile is a detailed strategic and analytical report on TESARO Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200View Report

TESARO Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

TESARO Inc Company Profile is a detailed strategic and analytical report on TESARO Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200View Report

TESARO Inc (TSRO) - Medical Equipment - Deals and Alliances Profile

TESARO Inc (TESARO) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates and discovery of new candidates. It develops products using different approaches, comprising small molecules

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Jul 2018
No. of Pages :80
Country :United States of America
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube